Mirati Therapeutics Management
Management criteria checks 4/4
Mirati Therapeutics' El consejero delegado es Chuck Baum , nombrado en Nov 2012, tiene un mandato de 11.08 años. la remuneración anual total es $7.42M , compuesta por 9.2% salario y 90.8% primas, incluidas acciones y opciones de la empresa. posee directamente 0.13% de las acciones de la empresa, por valor de $5.22M . La antigüedad media del equipo directivo y del consejo de administración es de 2.4 años y 5 años respectivamente.
Key information
Chuck Baum
Chief executive officer
US$7.4m
Total compensation
| CEO salary percentage | 9.2% |
| CEO tenure | 11.2yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.5yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Oct 05
Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?
Jun 22Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
May 17We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Feb 01Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates
Dec 09We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth
Oct 08Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?
Sep 11Mirati: A Potential Blockbuster Stock, Will Need Patience
Sep 08Mirati jumps 11% as Amgen meets key goal for rival cancer drug
Aug 31Mirati gains as Amgen posts new combination data for rival cancer drug
Aug 08Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
Aug 08Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years
Jun 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$726m |
| Jun 30 2023 | n/a | n/a | -US$738m |
| Mar 31 2023 | n/a | n/a | -US$737m |
| Dec 31 2022 | US$7m | US$685k | -US$741m |
| Sep 30 2022 | n/a | n/a | -US$738m |
| Jun 30 2022 | n/a | n/a | -US$645m |
| Mar 31 2022 | n/a | n/a | -US$634m |
| Dec 31 2021 | US$18m | US$662k | -US$582m |
| Sep 30 2021 | n/a | n/a | -US$483m |
| Jun 30 2021 | n/a | n/a | -US$491m |
| Mar 31 2021 | n/a | n/a | -US$407m |
| Dec 31 2020 | US$12m | US$615k | -US$358m |
| Sep 30 2020 | n/a | n/a | -US$329m |
| Jun 30 2020 | n/a | n/a | -US$296m |
| Mar 31 2020 | n/a | n/a | -US$259m |
| Dec 31 2019 | US$8m | US$597k | -US$213m |
| Sep 30 2019 | n/a | n/a | -US$169m |
| Jun 30 2019 | n/a | n/a | -US$142m |
| Mar 31 2019 | n/a | n/a | -US$125m |
| Dec 31 2018 | US$5m | US$580k | -US$98m |
| Sep 30 2018 | n/a | n/a | -US$88m |
| Jun 30 2018 | n/a | n/a | -US$77m |
| Mar 31 2018 | n/a | n/a | -US$67m |
| Dec 31 2017 | US$2m | US$563k | -US$70m |
Compensación vs. Mercado: La compensación total de Chuck ($USD7.42M) es aproximadamente el promedio para empresas de tamaño similar en el mercado US ($USD6.59M).
Compensación vs. Ingresos: La compensación de Chuck ha sido consistente con los resultados de la empresa en el último año.
CEO
Chuck Baum (65 yo)
11.2yrs
Tenure
US$7,420,213
Compensation
Dr. Charles M. Baum, M.D., Ph D., also known as Chuck, is a Director of Acrivon Therapeutics, Inc. from June 2023. Dr. Baum is an Independent Director of Poseida Therapeutics, Inc. from May 16, 2022.He se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 11.2yrs | US$7.42m | 0.16% $ 6.6m | |
| Executive VP & Chief Scientific Officer | 10yrs | US$5.01m | 0.082% $ 3.4m | |
| Executive VP & Chief Medical Officer | 1.2yrs | US$5.30m | 0.014% $ 587.2k | |
| Chief Financial Officer | less than a year | no data | 0.056% $ 2.3m | |
| Chief Accounting Officer | less than a year | no data | no data | |
| Chief Legal Officer & Corporate Secretary | less than a year | no data | no data | |
| Chief Compliance Officer | 2yrs | no data | no data | |
| Chief People Officer | 2yrs | no data | no data | |
| Chief Commercial Officer | 4yrs | US$6.93m | 0.040% $ 1.6m | |
| VP & Head of Medical Affairs | 3.8yrs | no data | no data | |
| VP & Head of Corporate Affairs | 3.8yrs | no data | no data | |
| Senior VP of Pharmacovigilance & Chief Safety Officer | 3yrs | no data | no data |
2.5yrs
Average Tenure
55yo
Average Age
Equipo directivo experimentado: MRTXEl equipo directivo de la empresa se considera experimentado (2.4 años de antigüedad media).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 11.2yrs | US$7.42m | 0.16% $ 6.6m | |
| Independent Director | 7.3yrs | US$700.41k | 0.0086% $ 353.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman & Lead Independent Director | 4.9yrs | US$979.79k | 0.012% $ 511.8k | |
| Independent Director | 4.6yrs | US$697.91k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.1yrs | US$677.91k | 0.061% $ 2.5m | |
| Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Independent Director | 10.3yrs | US$702.91k | 0.0086% $ 353.3k | |
| Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Independent Director | 5.1yrs | US$695.41k | 0.0086% $ 353.3k |
5.1yrs
Average Tenure
65yo
Average Age
Junta con experiencia: La junta directiva de MRTX se considera experimentada (5 años de antigüedad promedio).